Abstract
Objective: Tirzepatide is a novel, dual, glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, recently approved for the treatment of obesity, regardless of concomitant type 2 diabetes (T2D). The aim of the present meta-analysis was to assess the effect of tirzepatide on blood pressure (BP) levels in overweight/obese individuals without baseline T2D. Design and method: We searched PubMed and Cochrane Library databases, along with grey literature sources, from inception to December 2023, in order to retrieve randomized controlled trials (RCTs) assessing the effect of tirzepatide versus control on office systolic and diastolic BP (SBP and DBP, respectively) levels in patients with overweight/obesity without T2D at baseline. Results: We finally pooled data from 3 placebo controlled RCTs in a total of 3,788 randomized overweight/obese participants. Approximately one-third of enrolled participants had baseline hypertension. Baseline SBP and DBP levels across all eligible RCTs were within normal range. Subjects treated with tirzepatide (all doses) versus placebo experienced a significant reduction in both SBP by 7.3 mm Hg (p < 0.001) and DBP by 4.35 mm Hg (p < 0.001). Overall risk of bias was low for all eligible RCTs included in this analysis. Conclusions: In conclusion, preliminary evidence suggests that tirzepatide might produce a significant, beneficial effect on BP levels in overweight/obese subjects without T2D at baseline.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
